Skin carotenoid levels in adult patients with psoriasis.
Lima, X T, and A B Kimball. 2011. “Skin Carotenoid Levels in Adult Patients With Psoriasis.”. Journal of the European Academy of Dermatology and Venereology : JEADV 25 (8): 945-9.
Search
Search results
375 results found
Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory.
Gordon, K B, A B Kimball, D Chau, H N Viswanathan, J Li, D A Revicki, G Kricorian, and B G Ortmeier. 2014. “Impact of Brodalumab Treatment on Psoriasis Symptoms and Health-Related Quality of Life: Use of a Novel Patient-Reported Outcome Measure, the Psoriasis Symptom Inventory.”. The British Journal of Dermatology 170 (3): 705-15.
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.
Kimball, A B, K A Papp, Y Wasfi, D Chan, R Bissonnette, H Sofen, N Yeilding, et al. 2013. “Long-Term Efficacy of Ustekinumab in Patients With Moderate-to-Severe Psoriasis Treated for up to 5 Years in the PHOENIX 1 Study.”. Journal of the European Academy of Dermatology and Venereology : JEADV 27 (12): 1535-45.
Current guidelines for psoriasis treatment: a work in progress.
Golbari, Nicole M, Martina L Porter, and Alexa B Kimball. 2018. “Current Guidelines for Psoriasis Treatment: A Work in Progress.”. Cutis 101 (3S): 10-12.
Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension.
Kimball, Alexandra B, Thomas Luger, Alice Gottlieb, Luis Puig, Roland Kaufmann, Russel Burge, Chen-Yen Lin, and Gil Yosipovitch. 2018. “Long-Term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-Term Extension.”. Acta Dermato-Venereologica 98 (1): 98-102.
Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis.
Feldman, Steven R, Lawrence Green, Alexa B Kimball, Kimberly Siu, Yang Zhao, Vivian Herrera, Judit Nyirady, and Andrew F Alexis. 2017. “Secukinumab Improves Scalp Pain, Itching, Scaling and Quality of Life in Patients With Moderate-to-Severe Scalp Psoriasis.”. The Journal of Dermatological Treatment 28 (8): 716-21.
The temporal association between cutaneous T-cell lymphoma and psoriasis: implications for common biologic processes.
Donigan, J M, C Snowden, J B Carter, and A B Kimball. 2016. “The Temporal Association Between Cutaneous T-Cell Lymphoma and Psoriasis: Implications for Common Biologic Processes.”. Journal of the European Academy of Dermatology and Venereology : JEADV 30 (10): e31-e32.
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
Thaçi, Diamant, Ron Vender, Menno A de Rie, Curdin Conrad, David M Pariser, Bruce Strober, Veerle Vanvoorden, et al. 2023. “Safety and Efficacy of Bimekizumab through 2 Years in Patients With Moderate-to-Severe Plaque Psoriasis: Longer-Term Results from the BE SURE Randomized Controlled Trial and the Open-Label Extension from the BE BRIGHT Trial.”. The British Journal of Dermatology 188 (1): 22-31.
Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kimball, Alexa B, Lyn Guenther, Sunil Kalia, Elke M G J de Jong, Kimberly Parnell Lafferty, Dan Y Chen, Wayne Langholff, and Neil H Shear. 2021. “Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).”. JAMA Dermatology 157 (3): 301-6.
Impact of childhood atopic dermatitis on life decisions for caregivers and families.
Capozza, K, A Schwartz, J E Lang, J Chalmers, J Camilo, K Abuabara, K Kelley, et al. 2022. “Impact of Childhood Atopic Dermatitis on Life Decisions for Caregivers and Families.”. Journal of the European Academy of Dermatology and Venereology : JEADV 36 (6): e451-e454.